Ribavirin
- Generic Name
- Ribavirin
- Brand Names
- Ibavyr, Rebetol, Virazole
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O5
- CAS Number
- 36791-04-5
- Unique Ingredient Identifier
- 49717AWG6K
- Background
Producing a broad-spectrum activity against several RNA and DNA viruses, Ribavirin is a synthetic guanosine nucleoside and antiviral agent that interferes with the synthesis of viral mRNA. It is primarily indicated for use in treating hepatitis C and viral hemorrhagic fevers. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes...
- Indication
Indicated for the treatment of chronic Hepatitis C virus (HCV) infection in combination with other antiviral agents with the intent to cure or achieve a sustained virologic response (SVR). Typically added to improve SVR and reduce relapse rates .
...
- Associated Conditions
- Chronic Hepatitis C Virus (HCV) Infection, Severe Respiratory Syncytial Virus Infection
- Associated Therapies
- -
DAA in the Risk of Recurrence After Curative Treatment of HCC
- Conditions
- Interventions
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2017-08-07
- Lead Sponsor
- Taipei Veterans General Hospital, Taiwan
- Registration Number
- NCT02959359
Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)
- First Posted Date
- 2016-11-06
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 282
- Registration Number
- NCT02956629
Efficacy Study to Evaluate the Effect of New Antiviral Drugs on HCV Infection.
- Conditions
- Interventions
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2016-11-01
- Lead Sponsor
- University of Modena and Reggio Emilia
- Target Recruit Count
- 75
- Registration Number
- NCT02950870
- Locations
- 🇮🇹
Gastroenterology Unit, Modena, Italy
Pembrolizumab With or Without Elbasvir/Grazoprevir and Ribavirin in Treating Patients With Advanced Refractory Liver Cancer
- Conditions
- BCLC Stage B Hepatocellular CarcinomaStage IV Hepatocellular Carcinoma AJCC v7Stage IVA Hepatocellular Carcinoma AJCC v7BCLC Stage C Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v7Stage IIIB Hepatocellular Carcinoma AJCC v7Refractory Liver CarcinomaStage IVB Hepatocellular Carcinoma AJCC v7Hepatitis C InfectionStage IIIA Hepatocellular Carcinoma AJCC v7
- Interventions
- First Posted Date
- 2016-10-21
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT02940496
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
- Conditions
- Interventions
- First Posted Date
- 2016-10-20
- Last Posted Date
- 2022-05-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 33
- Registration Number
- NCT02939989
- Locations
- 🇺🇸
Ruane Clinical Research Group /ID# 155714, Los Angeles, California, United States
🇨🇳Beijing Di Tan Hospital, Capital Medical University /ID# 218496, Beijing, China
🇨🇦University of Calgary /ID# 155726, Calgary, Alberta, Canada
A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment
- Conditions
- Interventions
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2016-08-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 63
- Registration Number
- NCT02864199
APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and Ribavirin
- Conditions
- Interventions
- First Posted Date
- 2016-07-29
- Last Posted Date
- 2017-10-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 385
- Registration Number
- NCT02850289
Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen
- First Posted Date
- 2016-07-04
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 117
- Registration Number
- NCT02822794
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2019-10-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 256
- Registration Number
- NCT02803138
- Locations
- 🇮🇱
Ha'Emek Medical Center /ID# 153695, Afula, Israel
🇮🇱Assaf Harofeh Medical Center /ID# 153708, Be'er Ya'akov, Israel
🇮🇱The Edith Wolfson Medical Cent /ID# 153706, Holon, Israel
A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6
- Conditions
- Interventions
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2016-06-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT02791256
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.